An industry leading iPSC-based drug discovery platform
Patient-derived induced pluripotent stem cells (iPSCs) provide unique opportunities for phenotypic screening to identify new mechanisms of disease. Evotec has built an industrialised iPSC infrastructure that represents one of the largest and most sophisticated platforms in the industry. Evotec's iPSC platform has been developed over the last six years with the goal to industrialise iPSC-based drug screening in terms of throughput, reproducibility and robustness to reach highest industrial standards. This effort was initially enabled by a research collaboration with Harvard University involving world-leading scientists at the Harvard Stem Cell Institute. More recently, Evotec established collaborations with Celgene, Sanofi, Center for Regenerative Therapies Dresden, Censo Biotechnologies and Fraunhofer IME-SP to support Evotec's growing iPSC activities. In addition, we are working together with a number of academic institutions to further broaden and strengthen our iPSC capabilities.